Attached files

file filename
EX-99.1 - IMMUNIC, INC.e619758_ex99-1.htm




Washington, D.C. 20549




Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): July 2, 2020



(Exact name of registrant as specified in its charter)


Delaware 001-36201 56-2358443
(State or other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer Identification No.)

1200 Avenue of the Americas, Suite 200

New York, NY 10036


  (Address of principal executive offices)  


Registrant’s telephone number, including area code: 49 89 250079460


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of exchange on which registered
Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes No



Item 5.07 Submission of Matters to a Vote of Security Holders.


On July 2, 2020, Immunic, Inc. (the “Company”) held its annual meeting of stockholders (the “Meeting”). The total number of shares entitled to vote at the Meeting was 10,823,951 and there were present at the Meeting, in person or by proxy, 6,172,139 shares, which constituted a quorum for the Meeting. At the Meeting, the stockholders voted:


(1) to elect Dr. Vincent Ossipow and Mr. Jan Van den Bossche as directors for a three year term expiring at the 2023 annual meeting of stockholders; and


(2) to ratify the selection of Baker Tilly Virchow Krause, LLP as the Company’s independent registered public accounting firm, for the fiscal year ending December 31, 2020.


The final results of the stockholders votes at the Meeting are set forth below:


Proposal 1: Election of Directors


Dr. Vincent Ossipow   5,527,335   93,396   551,408
Jan Van den Bossche   5,526,774   93,957   551,408


Proposal 2: Ratification of Appointment of Baker Tilly as Independent Registered Public Accounting Firm


6,162,934   4,091   5,114   n/a


Item 7.01. Regulation FD Disclosure.


On July 8, 2020, Hella Kohlhof, Ph.D., the Company’s Chief Scientific Officer, will present at the Digital Novel Coronavirus Investment Forum about the Company’s clinical development program for IMU-838 as a potential treatment option for patients with COVID-19. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth therein.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits





Exhibit Description

99.1   Presentation, dated July 8, 2020





Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


Dated: July 7, 2020 Immunic, Inc.
  By: /s/ Daniel Vitt
    Daniel Vitt
    Chief Executive Officer